Drug Type Small molecule drug |
Synonyms Aquilda, SR-121463F (hydrochloride hydrate), 121463A (fumarate) + [3] |
Target |
Mechanism AVPR2 antagonists(Vasopressin V2 receptor antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Molecular FormulaC33H45N3O8S |
InChIKeyQKXJWFOKVQWEDZ-VCCCEUOBSA-N |
CAS Registry185913-78-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Satavaptan | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ascites | Phase 3 | US | 01 Jul 2006 | |
Ascites | Phase 3 | AR | 01 Jul 2006 | |
Ascites | Phase 3 | AU | 01 Jul 2006 | |
Ascites | Phase 3 | BE | 01 Jul 2006 | |
Ascites | Phase 3 | BA | 01 Jul 2006 | |
Ascites | Phase 3 | BG | 01 Jul 2006 | |
Ascites | Phase 3 | CA | 01 Jul 2006 | |
Ascites | Phase 3 | HR | 01 Jul 2006 | |
Ascites | Phase 3 | CZ | 01 Jul 2006 | |
Ascites | Phase 3 | DK | 01 Jul 2006 |
Phase 3 | 118 | Placebo | ounqjnikla(mklgxulgkn) = Higher rates of adverse events occurred with the 50 mg/day dose, including rapid correction of hyponatraemia mtzfohkqmg (dlrxhwwahr ) | - | 01 Mar 2011 | ||
Phase 2 | 151 | xekgjuljja(eyspywqltt) = lcqpvrpmhe pxgfrtrqvg (gyltwmgcyt ) | - | 01 Aug 2010 | |||
xekgjuljja(eyspywqltt) = gkdrbyzzof pxgfrtrqvg (gyltwmgcyt ) | |||||||
Phase 2 | 110 | lvfcmrrlxl(xtgvgvyxps) = Thirst was significantly more common in patients treated with satavaptan compared to those treated with placebo brhnweqgws (gxhxnerjoq ) | - | 01 Jul 2008 | |||